News items:


  • Cyclomics announces publication on CyclomicsSeq technology

    We are excited to announce the publication about Cyclomics’ core CyclomicsSeq technology in Genomic Medicine.  CyclomicsSeq technology involves a novel consensus sequencing approach fully optimised for circulating tumor DNA. The small size and low abundance of circulating tumor DNA in the blood of cancer patients makes accurate detection of cancer mutations difficult. Cyclomics has established a

    Read full news article


  • Appointment of Dàmi Rebergen as bioinformatician at Cyclomics

    We are happy to announce the appointment of Dàmi Rebergen to strengthen the bioinformatics capabilities of Cyclomics. Dàmi Rebergen has a bioinformatics degree from Wageningen University (2019) and has recent experience working at startup and biotech companies in The Netherlands and the UK. At Cyclomics, Dàmi will perform a key role in the establishment of a

    Read full news article


  • CyclomicsSeq manuscript available as preprint

    We are happy to announce the publication of our preprint manuscript about CyclomicsSeq on biorxiv.org. The manuscript describes our technology for capturing, amplifying, and high-accuracy sequencing of short circulating tumor DNA molecules from patients with cancer. We have developed CyclomicsSeq to be compatible with any long-read DNA sequencer and have extensively tested the technology with

    Read full news article


  • Cyclomics and University Medical Center Utrecht sign collaboration agreement

    Following the licensing of liquid biopsy technology owned by the University Medical Center Utrecht (UMC Utrecht), Cyclomics and the UMC Utrecht have entered into a long-standing collaboration to strengthen the synergy between both parties further, and drive technological innovation and clinical evaluation of the CyclomicsSeq platform technology. The agreement is an essential milestone for Cyclomics

    Read full news article


  • Cyclomics mentioned on Nature Methods

    Cyclomics was mentioned in Nature Methods Technology Feature The high-impact scientific journal Nature Methods has mentioned the Cyclomics founding team and technology in a recent article on Nanopore sequencing. The paper provides a historical overview of developments in Oxford Nanopore sequencing technology. One of the striking features of the Oxford Nanopore MinION instrument is the

    Read full news article


  • Cyclomics highlighted on GenomeWeb

    A recent article on the most read genomics news website, has featured an interview with Cyclomics founders Alessio Marcozzi and Jeroen de Ridder. The news item – which can be read in full on GenomeWeb – provides a comprehensive overview of the CyclomicsSeq technology for detection of cancer mutations in circulating tumor DNA. The article

    Read full news article


  • Cyclomics presents at LC 2019

    During the yearly London Calling conference, organised by Oxford Nanopore Technologies, Cyclomics CEO Jeroen de Ridder reported on recent results obtained from their CyclomicsSeq platform. The London Calling conference is a yearly event, that attracts over 600 academic and industrial researchers, who use the Oxford Nanopore sequencing platform for applications ranging from genome research, pathogen

    Read full news article


  • Cyclomics gets the SME Instrument grant

    Based on a well-balanced proposal describing further developments to strengthen their business case, Cyclomics received 50,000 EUR in funding from the European Commission, as part of the SME Instrument phase 1 program. The project proposal was put together in a collaborative effort with Catalyze, an Amsterdam-based Life Sciences consultancy company. “We are thrilled to receive

    Read full news article


  • Funds for clinical testing in collaboration with UMCU & NKI

    In a combined effort, Cyclomics in collaboration with the University Medical Center Utrecht and the Netherlands Cancer Institute, will test their circulating tumor DNA sequencing technology for recurrence detection and treatment response monitoring in patients with advanced stage head and neck cancer. More than 90% of patient with HPV-negative head and neck cancer contain mutations

    Read full news article


  • Cyclomics obtains the Take-Off grant

    Cyclomics and the University Medical Center Utrecht obtained 50.000 EUR in funding for further technical development and evaluation of their highly accurate mutation detection technology, which is based on proprietary DNA concatemerization technology and novel bioinformatics algorithms for mutation detection. Within the context of the Take Off grant, the Cyclomics team and researchers from the

    Read full news article


  • Cyclomics announces publication on CyclomicsSeq technology

    We are excited to announce the publication about Cyclomics’ core CyclomicsSeq technology in Genomic Medicine.  CyclomicsSeq technology involves a novel consensus sequencing approach fully optimised for circulating tumor DNA. The small size and low abundance of circulating tumor DNA in the blood of cancer patients makes accurate detection of cancer mutations difficult. Cyclomics has established a… Read More »Cyclomics announces publication on CyclomicsSeq technology